news

 

Cyril Amarchand Mangaldas has hired a fourth M&A partner in a month with the addition of Mohit Gogia from S&R Associates in New Delhi.

Gogia has over 18 years of experience advising on mergers and acquisitions, private equity and cross-border investment transactions and general corporate matters. He was an equity partner at S&R Associates, and previously worked at U.S. law firm Skadden, Arps, Slate, Meagher & Flom in New York.

Gogia’s hire comes as CAM looks to build its M&A capabilities across offices. In the last month, the firm hired partners Pooranimaa Hariharan from Trilegal, Alok Sonker from Krishnamurthy & Co, and Jay Parikh from Luthra and Luthra Law Offices.

CAM has also added a 50-lawyer capital markets team led by Manan Lahoty and employment partner Sowyma Kumar, both from IndusLaw, in the last two weeks.

The firm saw the departure of M&A-focused equity partner Shishir Vayttaden along with his team to Khaitan & Co in July.

“Mohit’s experience and expertise will be vital to our growth strategy and will augment our corporate practice in North India,” Ajay Sawhney, partner and head of CAM’s North India practice said in a statement.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, WFW act on $185 mln Adani Ports acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas advised its longstanding client Adani on Adani Ports and Special Economic Zone’s acquisition of 80 percent stake in Astro Offshore, an offshore support vessel operator. Watson Farley & Williams advised the selling shareholders of Astro Offshore.

Anagram adds M&A and PE partner from IndusLaw

by Nimitt Dixit |

M&A-focused Anagram Partners has become the latest to turn to IndusLaw to expand its offerings with the addition of M&A and private equity-focused partner Faraz Khan in Mumbai.

Trilegal, Latham, Quillon act on Platinum Equity’s India PE debut

by Nimitt Dixit |

Trilegal and Latham & Watkins have advised U.S.-based buyout fund Platinum Equity on its debut private equity deal in India, in the form of the acquisition of a majority stake in Inventia Healthcare, a Mumbai-based pharmaceutical company, at a valuation of $300 million.